Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Trial to Find and Investigate a Safe Dose of F16IL2 and BI 836858 in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation (PHIBI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03207191
Recruitment Status : Recruiting
First Posted : July 2, 2017
Last Update Posted : July 2, 2017
Sponsor:
Collaborator:
Boehringer Ingelheim
Information provided by (Responsible Party):
Philogen S.p.A.

Brief Summary:
Phase I, open label, single arm, non-randomized, multicenter, prospective dose escalation study in subjects with acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation (alloHSCT).

Condition or disease Intervention/treatment Phase
Acute Myeloid Leukemia (AML) Relapse Drug: F16IL2 Drug: BI 836858 Phase 1

Detailed Description:

The aim of the study is to determine a recommended dose for F16IL2 in combination with BI 836858 in AML relapse after alloHSCT and investigating safety and tolerability of the combination regimen.

Dose escalation will be guided by a Bayesian logistic regression model (BLRM) with overdose control that will be fitted to binary toxicity outcomes. The estimate of parameters will be updated as data are accumulated using the BLRM. At the end of the dose escalation phase, the probability of toxicity at each dose combination level will be calculated to determine an estimate of the MTD. Once the MTD or a biological active dose has been defined, additional patients (up to 10) will be treated with F16IL2 and BI 836858 dosed at this dose combination in order to confirm the safety profile of the combination.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 52 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With the Anti-CD33 Antibody BI 836858 in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation
Study Start Date : November 2016
Estimated Primary Completion Date : December 2018
Estimated Study Completion Date : December 2019


Arm Intervention/treatment
Experimental: F16IL2 + BI 836858

Successive cohorts of patients will receive increasing doses of FI6IL2 and BI 836858 until the MTD is reached. The MTD will be defined following a Bayesian logistic regression model (BLRM) with overdose control.

Patients will go off treatment after 6 months (i.e. after 6 cycles of induction combination therapy). Patients achieving CR or CRi will receive maintenance therapy for a maximum of 6 months.

Drug: F16IL2
F16IL2 dose escalation with provisional doses of 10, 20 and 30 Mio IU on Day 1, 8, 15 and 22 of each cycle through a rate-controlled intravenous infusion of 3 hours

Drug: BI 836858
BI 836858 dose escalation with provisional doses of 10, 20, 40, 80 and 160 mg on days 3, 10, 17 and 24 of each cycle through a rate-controlled intravenous infusion up to 5 hours




Primary Outcome Measures :
  1. Number of patients with adverse events that are related to treatment and classified as DLTs for each administered dosage [ Time Frame: Safety assessment will be performed from day 1 up to day 28 of the Cycle 1 (each cycle is 28 days) for every patient until the end of the enrollment ]
    To assess the dose limiting toxicity (DLT), maximum tolerated dose (MTD) and recommended dose (RD) of F16IL2 combined with BI 836858


Secondary Outcome Measures :
  1. Overall response rate (ORR) [ Time Frame: 1) from week 4 up to week 24, every 4 weeks; 2) for EoT: at week 26 (only induction) or 50 (plus maintenance); 3) for follow-up: from week 28 (only induction) or 52 (plus maintenance) up to week 76, every 4 weeks ]
  2. Relapse-free survival (RFS) [ Time Frame: 1) from week 4 up to week 24, every 4 weeks; 2) for EoT: at week 26 (only induction) or 50 (plus maintenance); 3) for follow-up: from week 28 (only induction) or 52 (plus maintenance) up to week 76, every 4 weeks ]
  3. Time to response (CR or CRi) of responding patients [ Time Frame: 1) from week 4 up to week 24, every 4 weeks; 2) for EoT: at week 26 (only induction) or 50 (plus maintenance); 3) for follow-up: from week 28 (only induction) or 52 (plus maintenance) up to week 76, every 4 weeks ]
  4. Overall survival (OS) rate [ Time Frame: From day 1 up to week 76, every 4 weeks ]
  5. Rate to complete donor chimerism [ Time Frame: 1) day 0; 2) from week 4 up to week 24, every 4 weeks; 3) for EoT: at week 26 (only induction) or 50 (plus maintenance); 4) for follow-up: from week 28 (only induction) or 52 (plus maintenance) up to week 76 every 4 weeks ]
  6. Time to complete donor chimerism [ Time Frame: 1) day 0; 2) from week 4 up to week 24, every 4 weeks; 3) for EoT: at week 26 (only induction) or 50 (plus maintenance); 4) for follow-up: from week 28 (only induction) or 52 (plus maintenance) up to week 76 every 4 weeks ]
  7. Maximum drug concentration [Cmax] [ Time Frame: Cycle 1,1) at day 1,2 (week 1); 2) at day 22,23 (week 4) ]
    Pharmacokinetics assessment of F16IL2 through blood sampling

  8. Time to reach maximum drug concentration [Tmax] [ Time Frame: Cycle 1,1) week 1; 2) week 4 ]
    Pharmacokinetics assessment of F16IL2 through blood sampling

  9. Terminal half-life [t1/2] [ Time Frame: Cycle 1,1) at day 1,2 (week 1); 2) at day 22,23 (week 4) ]
    Pharmacokinetics assessment of F16IL2 through blood sampling

  10. Area under the drug concentration-time curve [AUC(0 - t last)] and area under the drug concentration-time curve, extrapolated to infinity [AUC] [ Time Frame: Cycle 1, 1) at day 1,2 (week 1); 2) at day 22,23 (week 4) ]
    Pharmacokinetics assessment of F16IL2 through blood sampling

  11. Accumulation ratio for AUC [R AUC], Cmax [Rmax] and Cmin [R min] [ Time Frame: Cycle 1,1) at day 1,2 (week 1); 2) at day 22,23 (week 4) ]
    Pharmacokinetics assessment of F16IL2 through blood sampling

  12. Total clearance following the dose administered [CL] [ Time Frame: Cycle 1,1) at day 1,2 (week 1); 2) at day 22,23 (week 4) ]
    Pharmacokinetics assessment of F16IL2 through blood sampling

  13. Volume of distribution at steady state [Vss] [ Time Frame: Cycle 1,1) at day 1,2 (week 1); 2) at day 22,23 (week 4) ]
    Pharmacokinetics assessment of F16IL2 through blood sampling

  14. Mean residence time [MRT] [ Time Frame: Cycle 1,1) at day 1,2 (week 1); 2) at day 22,23 (week 4) ]
    Pharmacokinetics assessment of F16IL2 through blood sampling

  15. Maximum drug concentration [Cmax] [ Time Frame: Cycle 1 [at day 3,4,6 (week 1); at day 24,25,27 (week 4)] ]
    Pharmacokinetics assessment of BI 836858 through blood sampling

  16. Time to reach maximum drug concentration [Tmax] [ Time Frame: Cycle 1 [at day 3,4,6 (week 1); at day 24,25,27 (week 4)] ]
    Pharmacokinetics assessment of BI 836858 through blood sampling

  17. Terminal half-life [t1/2] [ Time Frame: Cycle 1 [at day 3,4,6 (week 1); at day 24,25,27 (week 4)] ]
    Pharmacokinetics assessment of BI 836858 through blood sampling

  18. Area under the drug concentration-time curve [AUC(0 - t last)] and area under the drug concentration-time curve, extrapolated to infinity [AUC] [ Time Frame: Cycle 1 [at day 3,4,6 (week 1); at day 24,25,27 (week 4)] ]
    Pharmacokinetics assessment of BI 836858 through blood sampling

  19. Accumulation ratio for AUC [R AUC], Cmax [Rmax] and Cmin [R min] [ Time Frame: Cycle 1 [at day 3,4,6 (week 1); at day 24,25,27 (week 4)] ]
    Pharmacokinetics assessment of BI 836858 through blood sampling

  20. Total clearance following the dose administered [CL] [ Time Frame: Cycle 1 [at day 3,4,6 (week 1); at day 24,25,27 (week 4); up to week 21, 22, 23, 24 of Cycle 6, every 4 weeks] ]
    Pharmacokinetics assessment of BI 836858 through blood sampling

  21. Volume of distribution at steady state [Vss] [ Time Frame: Cycle 1 [at day 3,4,6 (week 1); at day 24,25,27 (week 4)] ]
    Pharmacokinetics assessment of BI 836858 through blood sampling

  22. Mean residence time [MRT] [ Time Frame: Cycle 1 [at day 3,4,6 (week 1); at day 24,25,27 (week 4)] ]
    Pharmacokinetics assessment of BI 836858 through blood sampling

  23. Human anti-fusion protein antibodies (HAFA) levels [ Time Frame: 1) at day 1 of every 28 day cycle, from Cycle 1 up to Cycle 12; 2) for EoT: at week 26 (only induction) or 50 (plus maintenance); 3) for follow-up: at week 28 (only induction) or 52 (plus maintenance) ]
  24. BI 836858 anti-drug antibodies (ADAs) levels [ Time Frame: From Cycle 1 to Cycle 6, [at day 3 (week 1); at day 10 (week 2); at day 17 (week 3); at day 24 (week 4)] ]
  25. The rate of acute and chronic GvHD [ Time Frame: From day 1 up to week 76, every 4 weeks ]
  26. The severity of acute and chronic GvHD [ Time Frame: From day 1 up to week 76, every 4 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients with de novo or secondary AML according to the WHO/FAB classification relapsing after alloHSCT, and fulfilling at least one of the following:

    1. bone marrow blasts ≥ 5% of all nucleated cells
    2. appearance of blasts in the peripheral blood
    3. extramedullary AML relapse
  2. Age 18 - 75 years.
  3. ECOG ≤ 2.
  4. Documented negative test for HIV-HBV-HCV. For HBV serology: the determination of HBsAg, anti-HBsAg-Ab and anti-HBCAg-Ab is required. In patients with serology documenting previous exposure to HBV (i.e., anti-HBs Ab with no history of vaccination and/or anti-HBc Ab), negative serum HBV-DNA is required.
  5. Negative serum pregnancy test for females of childbearing potential* within 14 days of starting treatment.
  6. Informed consent personally signed and dated to participate in the study.
  7. Willingness and ability to comply with the scheduled visits, treatment plan, laboratory tests and other study procedures.

    • Women of childbearing potential (WOCBP) must be using, from the screening to six months following the last study drug administration, highly effective contraception methods, as defined by the "Recommendations for contraception and pregnancy testing in clinical trials" issued by the Head of Medicine Agencies' Clinical Trial Facilitation Group (www.hma.eu/ctfg.html) and which include, for instance, progesteron-only or combined (estrogen- and progesteron-containing) hormonal contraception associated with inhibition of ovulation, intrauterine devices, intrauterine hormone-releasing systems, bilateral tubal occlusion, vasectomized partner or sexual abstinence. Pregnancy test will be repeated at the end of treatment visit.

Women of childbearing potential are defined as females who have experienced menarche, are not postmenopausal (12 months with no menses without an alternative medical cause) and are not permanently sterilized (e.g., tubal occlusion, hysterectomy, bilateral oophorectomy or bilateral salpingectomy)

Exclusion Criteria:

  1. Known central nervous system manifestation of AML.
  2. Previous treatment (e.g., stem cell transplantation, chemotherapy, radiotherapy, investigational drugs) within 4 weeks or a minimum of 5 half-lifes of the treatment, whatever is shorter, of the first study drug intake for this current AML relapse after alloHSCT, except hydroxyurea to control peripheral cell counts up to one day before study medication.
  3. Active GvHD requiring systemic immunosuppression, unless controlled with low dose steroids equivalent to a maximum of 10 mg methylprednisolone per day.
  4. Chronically impaired renal function (estimated creatinine clearance < 30 ml/min).
  5. Inadequate liver function (ALT, AST, ALP or total bilirubin ≥ 3.0 x ULN), if not caused by leukemic infiltration.
  6. Any severe concomitant condition which makes it undesirable for the patient to participate in the study or which could jeopardize compliance with the protocol.
  7. History within the last year of acute or subacute coronary syndromes including myocardial infarction, unstable or severe stable angina pectoris.
  8. Heart insufficiency (> Grade II, New York Heart Association (NYHA) criteria).
  9. Irreversible cardiac arrhythmias requiring permanent medication.
  10. Uncontrolled hypertension.
  11. Ischemic peripheral vascular disease (Grade IIb-IV).
  12. Severe diabetic retinopathy such as severe non-proliferative retinopathy and proliferative retinopathy.
  13. Major trauma including major surgery (such as abdominal/cardiac/thoracic surgery) within 4 weeks of administration of study treatment.
  14. Pregnancy or breast-feeding.
  15. Requirement of chronic administration of corticosteroids. However, low dose corticosteroids (maximum 10 mg methylprednisolone or equivalent per day when administered for GVHD) are allowed.
  16. Presence of active and uncontrolled infections or other severe concurrent disease, which, in the opinion of the investigator, would place the patient at undue risk or interfere with the study.
  17. Known active or latent tuberculosis (TB).
  18. Known hereditary fructose intolerance.
  19. Concurrent malignancies other than AML (except basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast) unless the patient has been disease-free for at least 2 years.
  20. Concomitant treatment with angiogenesis inhibitors or other drugs with proven anti-leukemic activity.
  21. Prior treatment with CD33 antibody.
  22. Serious, non-healing wound, ulcer or bone fracture.
  23. Allergy to study medication or excipients in study medication.
  24. Concurrent use of other anti-cancer treatments or agents.
  25. Failure to fulfil inclusion criteria.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03207191


Contacts
Layout table for location contacts
Contact: Teresa Hemmerle, PhD +39 057717816 regulatory@philogen.com
Contact: Serena Bettarini, Dr +39 057717816 regulatory@philogen.com

Locations
Layout table for location information
Germany
University Medical Center Freiburg Not yet recruiting
Freiburg, Germany
Principal Investigator: Hartmut Bertz, MD         
Münster University Hospital Recruiting
Münster, Germany
Principal Investigator: Christoph Schliemann, MD         
Sponsors and Collaborators
Philogen S.p.A.
Boehringer Ingelheim

Layout table for additonal information
Responsible Party: Philogen S.p.A.
ClinicalTrials.gov Identifier: NCT03207191     History of Changes
Other Study ID Numbers: PH-F16IL2CD33-03/15
First Posted: July 2, 2017    Key Record Dates
Last Update Posted: July 2, 2017
Last Verified: November 2016

Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia, Myeloid, Acute
Recurrence
Leukemia, Myeloid
Leukemia
Neoplasms by Histologic Type
Neoplasms
Disease Attributes
Pathologic Processes
Interleukin-2
Antineoplastic Agents
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs